GlassScriptPhysician profile
Renee Rhem
NPI 1346509239
$15,131.91
in general payments reported to CMS, 2019-2025
31 companies · $4,330 in 2025
The $4,330 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,388 · 2022: $3,268 · 2023: $2,566 · 2024: $2,580 · 2025: $4,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,380 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,380.38 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,842.13 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $2,563.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,048.50 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $1,164.63 | 2022-2025 | Haegarda, Andembry, Kcentra |
| Abbvie INC. | $803.73 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $802.82 | 2021-2023 | Dupixent |
| Biocryst US Sales Co., LLC | $746.87 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $498.70 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $418.53 | 2021-2023 | |
| Kaleo, INC. | $372.49 | 2021-2024 | Auvi-Q |
| Incyte Corporation | $368.48 | 2021-2023 | Opzelura |
| Amgen INC. | $333.00 | 2021-2025 | Tezspire |
| Galderma Laboratories, L.P. | $293.79 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $277.29 | 2022-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $236.54 | 2025 | Neffy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $180.39 | 2024-2025 | Ebglyss |
| Pfizer INC. | $154.05 | 2021-2024 | |
| Grifols USA, LLC | $147.85 | 2022-2025 | Xembify |
| Ionis Pharmaceuticals, INC. | $139.42 | 2025 | Dawnzera |
| Organon LLC | $137.34 | 2025 | Vtama |
| Convatec INC. | $135.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.93 | 2021-2025 | Takhzyro |
| Sanofi-Aventis U.S. LLC | $115.71 | 2021-2025 | |
| Optinose US, INC. | $51.40 | 2021 | |
| Genentech USA, INC. | $37.78 | 2022-2023 | Xolair |
| Aimmune Therapeutics, INC. | $25.01 | 2021-2022 | |
| Mylan Specialty L.P. | $24.03 | 2022 | |
| Alk-Abello, INC | $21.25 | 2021 | |
| Pharming Healthcare, INC. | $20.39 | 2021 | |
| Cipher Pharmaceuticals US LLC | $19.01 | 2025 | Natroba, Spinosad |
| Hikma Pharmaceuticals USA | $18.23 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Rhem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.